Vericel CorpVCELEarnings & Financial Report
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
VCEL Q4 FY2025 Key Financial Metrics
Revenue
$92.9M
Gross Profit
$73.1M
Operating Profit
$22.4M
Net Profit
$23.2M
Gross Margin
78.7%
Operating Margin
24.1%
Net Margin
25.0%
YoY Growth
23.3%
EPS
$0.46
Vericel Corp Q4 FY2025 Financial Summary
Vericel Corp reported revenue of $92.9M (up 23.3% YoY) for Q4 FY2025, with a net profit of $23.2M (up 17.3% YoY) (25.0% margin). Cost of goods sold was $19.8M, operating expenses totaled $50.7M.
Key Financial Metrics
| Total Revenue | $92.9M |
|---|---|
| Net Profit | $23.2M |
| Gross Margin | 78.7% |
| Operating Margin | 24.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Vericel Corp Q4 FY2025 revenue of $92.9M breaks down across 2 segments, led by MACI Implants And Kits at $84.1M (90.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| MACI Implants And Kits | $84.1M | 90.5% |
| Other | $8.8M | 9.5% |
Vericel Corp Revenue by Segment — Quarterly Trend
Vericel Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as MACI Implants And Kits and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| MACI Implants And Kits | $84.1M | $55.7M | $53.5M | $46.3M |
| Other | $8.8M | $11.8M | $9.8M | $5.2M |
Vericel Corp Annual Revenue by Year
Vericel Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $276.3M).
Vericel Corp Quarterly Revenue & Net Profit History
Vericel Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $92.9M | +23.3% | $23.2M | 25.0% |
| Q3 FY2025 | $67.5M | +16.6% | $5.1M | 7.5% |
| Q2 FY2025 | $63.2M | +20.1% | $-553.0K | -0.9% |
| Q1 FY2025 | $52.6M | +2.6% | $-11.2M | -21.4% |
| Q4 FY2024 | $75.4M | +16.0% | $19.8M | 26.3% |
| Q3 FY2024 | $57.9M | +27.0% | $-901.0K | -1.6% |
| Q2 FY2024 | $52.7M | +14.7% | $-4.7M | -8.9% |
| Q1 FY2024 | $51.3M | +25.0% | $-3.9M | -7.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $51.3M | $52.7M | $57.9M | $75.4M | $52.6M | $63.2M | $67.5M | $92.9M |
| YoY Growth | 25.0% | 14.7% | 27.0% | 16.0% | 2.6% | 20.1% | 16.6% | 23.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $356.7M | $376.8M | $390.4M | $432.7M | $424.6M | $435.6M | $453.3M | $488.0M |
| Liabilities | $122.8M | $133.9M | $132.9M | $140.8M | $129.1M | $128.8M | $131.4M | $133.3M |
| Equity | $233.9M | $243.0M | $257.5M | $292.0M | $295.5M | $306.8M | $321.9M | $354.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.2M | $18.5M | $10.2M | $22.2M | $6.6M | $8.2M | $22.1M | $15.0M |